Table 2.
Type of pharmacological treatment prescribed after the initial diagnosis of hormonally functional PHAEO/PGL.
| Type of treatment | Patients, n (%) |
|---|---|
| Appropriate treatment (n = 264) | |
| α-Adrenoceptor blockers alone | 149 (56.4) |
| α-Adrenoceptor blockers followed by β-adrenoceptor blockers | 78 (29.5) |
| α-Adrenoceptor blockers with CCBs | 8 (3) |
| α-Adrenoceptor blockers with metyrosine | 7 (2.7) |
| α-Adrenoceptor blockers with ACE inhibitors | 3 (1.1) |
| α-Adrenoceptor blockers with ARBs | 1 (0.4) |
| CCBs alone | 16 (6.1) |
| CCBs with ACE inhibitors | 1 (0.4) |
| CCBs with ARBs | 1 (0.4) |
| Inappropriate treatment (n = 117) | |
| No treatment | 62 (53) |
| β-Adrenoceptor blockers and α-adrenoceptor blockers at the same time | 14 (12) |
| β-Adrenoceptor blockers alone | 11 (9.4) |
| Combined α- and β-adrenoceptor blockers | 9 (7.7) |
| β-Adrenoceptor blockers with CCBs | 5 (4.3) |
| β-Adrenoceptor blockers with ACE inhibitors | 1 (0.9) |
| β-Adrenoceptor blockers with ARBs | 1 (0.9) |
| β-Adrenoceptor blockers with clonidine | 1 (0.9) |
| ACE inhibitors alone | 8 (6.8) |
| ARBs alone | 5 (4.3) |
ACE inhibitors = angiotensin-converting enzyme inhibitors; ARBs = angiotensin II receptor blockers; CCBs = calcium channel blockers; metyrosine = α-methyl-ρ-tyrosine; PHAEO/PGL = phaeochromocytoma and paraganglioma.